We receive from a reliable and accredited Roche source and gladly publish [Editor's note]
On 17 November, Roche's CEO said he was sorry that the operation for the sale of the business unit with Quintiles would not go ahead because it would not be convenient from an economic point of view (it was not understood whether the lack of convenience was for Roche or for Quintiles and because they have discovered it only now given that the products whose scientific information service would have been sold have 20 to 30 years of life).
However, it seems to us the demonstration that this operation, for which almost all the procedures required by law had already been completed and which could have already seen us in Quintiles within three days without further bureaucratic steps, was truly a farce.
This system, successfully tested in the pharmaceutical sector, to precarious jobs at very low cost for the transferring company has clamorously jammed in Roche, one of the largest drug multinationals.
The determination and unity of 70 people, who found themselves overnight with the sack of a company to which they have given their service and dedication for so many years, was enough to make a decision that seemed now irrevocable.
At this moment we do not know what the company's next moves will be, which in the meantime has presented, albeit summarily, the Opex project, which still involves personnel cuts.
However, we remain determined to defend our dignity and our workplace with all the means at our disposal.
Roche balance sheet 2009
Despite the extremely difficult context for the Italian pharmaceutical sector and the global economic crisis, Roche recorded an extremely positive performance in 2009.
Turnover was 1,047.9 million euros which corresponds to a growth rate of 7.9% compared to the previous year. The net profit recorded in the year was 28.1 million euro.
In the ranking of Italian pharmaceutical companies, Roche continues to be the undisputed leader in the hospital market, where it ranks first with a market share of 11.1%, and has reached second place in the general ranking of Italian pharmaceutical companies, with a of 5.8%.
[Source: Roche website]
